Matches in Nanopublications for { <http://www.tkuhn.ch/bel2nanopub/RAUnatTAx72bZIAiovFmF7SSrKuiJ9NThgm9Hb9Udz2ik#_4> ?p ?o ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- _4 value "IL-6 treatment led to activation of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3'-kinase (PI3K) pathways. Inhibition of MAPK or PI3K activity reversed IL-6- and oncostatin M-stimulated migration. For transient transfections, plasmids were introduced into the cells using Superfect transfection reagent (Qiagen). A HA-tagged MAPK (Erk2) construct (kindly provided by M. El-Shemerly and Y. Nagamine; Friedrich Miescher Institute, Basel, Switzerland) was cotransfected with a DN EGF receptor construct lacking 533 COOH-terminal amino acids MAPK kinase inhibitors PD98059 (20 uM; New England Biolabs) or UO126 (50 uM; Promega, Madison, WI PD98059, which is known to specifically inhibit the ERK-activating kinase MEK1, has been widely used to assess the effects of dampening ERK activation. MEK inhibitor UO126 (Promega, MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2)." provenance.
- _4 wasQuotedFrom 11196191 provenance.